1. Home
  2. AVXL vs FNA Comparison

AVXL vs FNA Comparison

Compare AVXL & FNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVXL
  • FNA
  • Stock Information
  • Founded
  • AVXL 2001
  • FNA 2010
  • Country
  • AVXL United States
  • FNA United States
  • Employees
  • AVXL N/A
  • FNA N/A
  • Industry
  • AVXL Biotechnology: Biological Products (No Diagnostic Substances)
  • FNA Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • AVXL Health Care
  • FNA Health Care
  • Exchange
  • AVXL Nasdaq
  • FNA Nasdaq
  • Market Cap
  • AVXL 779.5M
  • FNA 910.9M
  • IPO Year
  • AVXL N/A
  • FNA 2021
  • Fundamental
  • Price
  • AVXL $8.35
  • FNA $13.03
  • Analyst Decision
  • AVXL Strong Buy
  • FNA Buy
  • Analyst Count
  • AVXL 2
  • FNA 7
  • Target Price
  • AVXL $44.00
  • FNA $15.20
  • AVG Volume (30 Days)
  • AVXL 995.5K
  • FNA 2.4M
  • Earning Date
  • AVXL 02-12-2025
  • FNA 03-03-2025
  • Dividend Yield
  • AVXL N/A
  • FNA N/A
  • EPS Growth
  • AVXL N/A
  • FNA N/A
  • EPS
  • AVXL N/A
  • FNA N/A
  • Revenue
  • AVXL N/A
  • FNA $244,995,000.00
  • Revenue This Year
  • AVXL N/A
  • FNA $19.14
  • Revenue Next Year
  • AVXL N/A
  • FNA $14.16
  • P/E Ratio
  • AVXL N/A
  • FNA N/A
  • Revenue Growth
  • AVXL N/A
  • FNA 18.16
  • 52 Week Low
  • AVXL $3.25
  • FNA $4.65
  • 52 Week High
  • AVXL $14.44
  • FNA $13.59
  • Technical
  • Relative Strength Index (RSI)
  • AVXL 40.39
  • FNA 74.47
  • Support Level
  • AVXL $8.50
  • FNA $10.11
  • Resistance Level
  • AVXL $9.20
  • FNA $13.08
  • Average True Range (ATR)
  • AVXL 0.49
  • FNA 0.04
  • MACD
  • AVXL -0.01
  • FNA -0.09
  • Stochastic Oscillator
  • AVXL 32.23
  • FNA 35.00

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.

About FNA Paragon 28 Inc.

Paragon 28 Inc is a medical devices company that develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace. Its products include plates and plating systems, screws, staples, and nails aimed to address all major foot and ankle procedures including ankle, Charcot, fracture fixation, hallux valgus, hammertoe, and flat foot. The company's suite of surgical solutions comprises nearly 80 product systems to help fit the specific needs of each patient and procedure. Geographically the company generates the majority of its revenue from the United States.

Share on Social Networks: